
GlySens
3931 Sorrento Valley Blvd Suite 110, San Diego, California, 92121, United States
Overview
GlySens develops the GlySens ICGM® system, an implantable continuous glucose monitoring solution consisting of a fully implanted sensor and an external receiver/monitor. The implanted sensor is designed for long operational life and the system provides glucose reporting and alerts for hypo- and hyperglycemic excursions. The company is led by President and CEO William Markle and co-founder/CTO Joseph Lucisano, PhD. GlySens is based in San Diego, California. It closed a $20M Series D financing to support its next steps. The company plans to use the funds to expand clinical trials to support a CE‑Marking application, hire additional staff, and complete the build-out of a new facility and optimized manufacturing plant. GlySens develops an implantable continuous glucose monitoring system for people with diabetes. Its implantable sensor offers a one-year battery life and wirelessly transmits glucose data to an external receiver for display and logging. The system operates without any through-the-skin or skin-attached elements. The company is led by Joseph Lucisano and is based in San Diego, CA. In May 2015 GlySens raised $12M in Series C funding. The company intends to use the funds for further development of its systems, and the round included both new and returning investors. GlySens is developing an implantable, long-term continuous glucose sensor system intended to monitor glucose levels and enhance diabetes care. The sensor is designed to reside completely beneath the skin and transmit glucose measurements wirelessly to a convenient external display device. The company is led by President and CEO Joseph Y. Lucisano, PhD, and its scientific advisor and co-founder is David A. Gough, PhD. GlySens is based in San Diego, CA. The company received an investment from the West Health Investment Fund; the amount and terms were not disclosed. GlySens says the system is intended to help patients control their blood sugar levels more effectively.
- Total raised
- $32M
- Funding rounds
- 3
- Latest round
- Series D
- Latest activity
- Jan 2016
Industries
- Health Care
- Manufacturing
- Medical Device
Recent funding
Series D
Jan 2016
$20M
Series C
Jan 2015
$12M
Team
No current team members are available.